Trump announces efforts to expand access to IVF drugs

Trump announces efforts to expand access to IVF drugs


U.S. President Donald Trump delivers remarks before signing an executive order on expanding access to IVF at his Mar-a-Lago resort on Feb. 18, 2025 in Palm Beach, Florida.

Joe Raedle | Getty Images

President Donald Trump on Thursday announced two new efforts to expand the availability of in vitro fertilization, the first concrete step from his administration on the expensive and politically fraught procedure.

Trump struck a deal with EMD Serono, a subsidiary of Germany’s Merck KGaA, to slash the price of some of the company’s fertility medicines in exchange for relief from planned tariffs on pharmaceuticals imported into the U.S., which Trump has not yet imposed.

The Trump administration will also be issuing guidance encouraging employers to offer fertility benefits directly to their employees, which would work similarly to vision or dental coverage. It will allow employers to offer add-on coverage at a fixed cost for patients and employers. But it’s unclear how much the effort will increase coverage, as it does not mandate that employers participate.

At a press conference Thursday, Trump said the moves will lead to “many more beautiful American children.”

“We’ll dramatically slash the cost of IVF and the treatment and many of the most common fertility drugs for countless millions of Americans,” Trump said. “Prices are going way down, way, way down.”

EMD Serono, the largest fertility drug manufacturer in the world, said it will sell its IVF therapies directly to patients and that people will be able to buy the drugs on Trump’s direct-to-consumer purchasing site, TrumpRx.gov. That site will launch in January 2026.

The medications include Gonal-f, a critical drug used in the shot protocol required for egg stimulation.

The plan comes as Trump works to rein in prescription drug costs in the U.S., inking deals with Pfizer and AstraZeneca in recent weeks that aim to make it easier for Americans to access certain drugs.

Millions of babies have been born through IVF, which involves combining eggs and sperm in a laboratory to create an embryo for couples having difficulty conceiving. The decades-old procedure is an issue that the president repeatedly vowed to address on the campaign trail, calling himself the “father of IVF” last fall.

The procedure is often not fully covered by insurance — if at all — and it can cost around $20,000 or more per cycle. Only a quarter of companies with more than 200 employees currently cover IVF. Some studies have shown that an IVF cycle in the U.S. costs 271% more than the average in 25 other countries. 

Trump issued an executive order on IVF shortly after the president took office, promising to lower costs and make the procedure more accessible. But that order did not provide specifics apart from promising to put out a detailed report with recommendations on the issue by late May. That report has not been released. 

The procedure became a flashpoint in the nationwide clash over abortion and reproductive rights in early 2024 when Alabama’s Supreme Court said that frozen embryos are children and those who destroy them can be held liable for wrongful death. In some cases, embryos may be discarded during IVF. 

Trump quickly distanced himself from that ruling last year, urging the Alabama Legislature to protect access to IVF. 

Americans generally support the procedure. An April 2024 poll from Pew Research Center found that seven in 10 U.S. adults say IVF access is a good thing, with modest differences across most demographic and partisan groups. 



Source

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More
UnitedHealth Group commits to improvements after independent audit, patient backlash
Health

UnitedHealth Group commits to improvements after independent audit, patient backlash

UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in three specific areas. The health-care […]

Read More